Patient no.	Age^a/Sex	FAB^b,c	Disease status^d	Cytogenetics^e	Cytogenetics risk group at relapse	Remission duration (months)^f	Previous treatments		GO reinduction
Patient no.	Age^a/Sex	FAB^b,c	Disease status^d	Cytogenetics^e	Cytogenetics risk group at relapse	Remission duration (months)^f	Remission induction^g,h,i	Consolidation^j,k	GO reinduction
1	65/M	M6	Non-CR	complex karyotype	Unfavorable	^*	IDA + AraC	-	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 4
2	19/F	M1	Non-CR	46, XX	Intermediate	^*	IDA + AraC	-	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 4
3	81/M	MDS (RA) ⇒ M2	Non-CR	46, XY	Intermediate	^*	IDA + BHAC	-	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 4
4	56/F	M1	Non-CR	Not Available	Not Available	^*	IDA + AraC	-	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 7
5	73/M	M2	First relapse	46, XY	Intermediate	5	CAG	IDA + AraC, BHAC-DM	AraC 100 mg/m² on days 1 - 5		+GO 6 mg/m² on day 6
6	71/M	MDS (RA) ⇒ M2	First relapse	complex karyotype	Unfavorable	10	IDA + AraC	HDAraC + MIT, ×3	AraC 2000 mg/m² on days 1-5		+GO 6 mg/m² on day 6
7	42/M	M0	First relapse	46, XY	Intermediate	19	IDA + AraC	HDAraC + MIT, ×2	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 7
8	67/M	M0	First relapse	46, XY	Intermediate	4	IDA + AraC	HDAraC + MIT, ×3	AraC 2000 mg/m² on days 1 - 5	+IDA 6 mg/m² on days 1 - 3	+GO 6 mg/m² on day 7
9	62/M	Essential thrombocythemia ⇒ M2	First relapse	46, XY	Intermediate	2	IDA + AraC	HDAraC + MIT, ×1	AraC 2000 mg/m² on days 1 - 5	+MIT 12 mg/m² on days 1 - 3	+GO 6 mg/m² on day 4